Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand'Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J; Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP. Spelman T, et al. Among authors: lalive p. Front Neurol. 2023 Dec 22;14:1274194. doi: 10.3389/fneur.2023.1274194. eCollection 2023. Front Neurol. 2023. PMID: 38187157 Free PMC article.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
Dekeyser C, Hautekeete M, Cambron M, Van Pesch V, Patti F, Kuhle J, Khoury S, Lechner Scott J, Gerlach O, Lugaresi A, Maimone D, Surcinelli A, Grammond P, Kalincik T, Habek M, Willekens B, Macdonell R, Lalive P, Csepany T, Butzkueven H, Boz C, Tomassini V, Foschi M, Sánchez-Menoyo JL, Altintas A, Mrabet S, Iuliano G, Sa MJ, Alroughani R, Karabudak R, Aguera-Morales E, Gray O, de Gans K, van der Walt A, McCombe PA, Deri N, Garber J, Al-Asmi A, Skibina O, Duquette P, Cartechini E, Spitaleri D, Gouider R, Soysal A, Van Hijfte L, Slee M, Amato MP, Buzzard K, Laureys G. Dekeyser C, et al. Among authors: lalive p. J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307. doi: 10.1136/jnnp-2023-333307. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38569872
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Disanto G, et al. Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954. Ann Neurol. 2017. PMID: 28512753 Free PMC article.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board. Disanto G, et al. Among authors: lalive ph. PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016. PLoS One. 2016. PMID: 27032105 Free PMC article.
[Novel immunomodulatory therapies in myasthenia gravis].
Sukockiené E, Théaudin M, Loser V, Staedler K, Lalive PH, Lascano AM. Sukockiené E, et al. Among authors: lalive ph. Rev Med Suisse. 2024 Apr 24;20(871):848-851. doi: 10.53738/REVMED.2024.20.871.848. Rev Med Suisse. 2024. PMID: 38665106 Review. French.
[Discontinuing disease-modifying therapies in multiple sclerosis].
Bernard-Valnet R, Lalive PH, Bréville G, Théaudin M, Pot C, Du Pasquier R. Bernard-Valnet R, et al. Among authors: lalive ph. Rev Med Suisse. 2024 Apr 24;20(871):843-847. doi: 10.53738/REVMED.2024.20.871.843. Rev Med Suisse. 2024. PMID: 38665105 French.
[Treatments for multiple sclerosis: update].
Uginet M, Lefeuvre L, Lerusse J, Pot C, Du Pasquier R, Lalive PH. Uginet M, et al. Among authors: lalive ph. Rev Med Suisse. 2024 Apr 24;20(871):837-842. doi: 10.53738/REVMED.2024.20.871.837. Rev Med Suisse. 2024. PMID: 38665104 Review. French.
[Anti-MOG associated disease].
Lerusse J, Uginet M, Théaudin M, Bernard-Valnet R, Pot C, Lalive PH. Lerusse J, et al. Among authors: lalive ph. Rev Med Suisse. 2024 Apr 24;20(871):828-832. doi: 10.53738/REVMED.2024.20.871.828. Rev Med Suisse. 2024. PMID: 38665102 French.
[The diagnostic challenge of autoimmune encephalitis].
Di Liberto G, Uginet M, Lalive PH, Du Pasquier R. Di Liberto G, et al. Among authors: lalive ph. Rev Med Suisse. 2024 Apr 24;20(871):822-827. doi: 10.53738/REVMED.2024.20.871.822. Rev Med Suisse. 2024. PMID: 38665101 French.
189 results